晨化股份(300610.SZ):5名股東減持期屆滿 合計減持1.83%股份
格隆匯9月24日丨晨化股份(300610.SZ)公佈,公司近日收到持股5%以上股東徐長勝(首發時任公司副總經理,後於2018年12月28日離任)及其一致行動人徐長俊,發行前持股5%以上股東、董事、副總經理楊思學(首發至今任董事、副總經理)及其一致行動人楊思傑,監事郝斌(2019年6月24日至今任公司監事會主席)出具的《公司股份減持實施情況告知函》,上述股東減持計劃時間已屆滿。
自2020年3月24日-9月22期間,上述股東通過集中競價方式合計減持公司股份276.4741萬股,佔公司總股本的1.83%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.